Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 26Lymphoma, Non-Hodgkin 22Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 14Lymphoma, Follicular 13Recurrence 12Waldenstrom Macroglobulinemia 9Neoplasms 8Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphoid 6Leukemia, B-Cell 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Myeloid, Acute 3Leukemia 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Neoplasms 3Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1

Interventions

Carboplatin 369Pemetrexed 310pembrolizumab 303Cisplatin 244Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28tislelizumab 26cemiplimab 26avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × ibrutinib × Clear all
NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡